554 related articles for article (PubMed ID: 1412162)
1. Vampire bat salivary plasminogen activator promotes robust lysis of plasma clots in a plasma milieu without causing fluid phase plasminogen activation.
Hare TR; Gardell SJ
Thromb Haemost; 1992 Aug; 68(2):165-9. PubMed ID: 1412162
[TBL] [Abstract][Full Text] [Related]
2. Vampire bat salivary plasminogen activator evokes minimal bleeding relative to tissue-type plasminogen activator as assessed by a rabbit cuticle bleeding time model.
Mellott MJ; Ramjit DR; Stabilito II; Hare TR; Senderak ET; Lynch JJ; Gardell SJ
Thromb Haemost; 1995 Mar; 73(3):478-83. PubMed ID: 7545321
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the relative fibrinogenolytic, fibrinolytic and thrombolytic properties of tissue plasminogen activator and urokinase in vitro.
Matsuo O; Rijken DC; Collen D
Thromb Haemost; 1981 Jun; 45(3):225-9. PubMed ID: 7025339
[TBL] [Abstract][Full Text] [Related]
4. Fluorogenic fibrinogen and fibrin facilitate macromolecular assembly and dynamic assay of picomolar levels of plasminogen activators under well mixed conditions.
Wu JH; Diamond SL
Thromb Haemost; 1995 Aug; 74(2):711-7. PubMed ID: 8585011
[TBL] [Abstract][Full Text] [Related]
5. Soluble fibrin degradation products potentiate tissue plasminogen activator-induced fibrinogen proteolysis.
Weitz JI; Leslie B; Ginsberg J
J Clin Invest; 1991 Mar; 87(3):1082-90. PubMed ID: 1900308
[TBL] [Abstract][Full Text] [Related]
6. Rapid dissociation of platelet-rich fibrin clots in vitro by a combination of plasminogen activators and antiplatelet agents.
Lam SC; Dieter JP; Strebel LC; Taylor TM; Muscolino G; Feinberg H; Le Breton GC
J Pharmacol Exp Ther; 1991 Dec; 259(3):1371-8. PubMed ID: 1762085
[TBL] [Abstract][Full Text] [Related]
7. [Intensification of the effect of exogenous plasminogen activators on lysis of fibrin blood clots due to a decrease in the level of alpha-2- antiplasmin by a plasmasorption method].
Ogloblina OG; Saburova OS; Semenova OA; Belova LA
Biokhimiia; 1994 Jan; 59(1):62-8. PubMed ID: 7509643
[TBL] [Abstract][Full Text] [Related]
8. Mechanisms of activation of mammalian plasma fibrinolytic systems with streptokinase and with recombinant staphylokinase.
Collen D; Van Hoef B; Schlott B; Hartmann M; Gührs KH; Lijnen HR
Eur J Biochem; 1993 Aug; 216(1):307-14. PubMed ID: 7689966
[TBL] [Abstract][Full Text] [Related]
9. Absence of synergism between tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (scu-PA) and urokinase on clot lysis in a plasma milieu in vitro.
Collen D; De Cock F; Demarsin E; Lijnen HR; Stump DC
Thromb Haemost; 1986 Aug; 56(1):35-9. PubMed ID: 3095946
[TBL] [Abstract][Full Text] [Related]
10. Fibrin clot lysis by thrombolytic agents is impaired in newborns due to a low plasminogen concentration.
Andrew M; Brooker L; Leaker M; Paes B; Weitz J
Thromb Haemost; 1992 Sep; 68(3):325-30. PubMed ID: 1440499
[TBL] [Abstract][Full Text] [Related]
11. Effect of retraction on the lysis of human clots with fibrin specific and non-fibrin specific plasminogen activators.
Sabovic M; Lijnen HR; Keber D; Collen D
Thromb Haemost; 1989 Dec; 62(4):1083-7. PubMed ID: 2515603
[TBL] [Abstract][Full Text] [Related]
12. The antifibrinolytic effects of carbon monoxide-releasing molecule-2 are fibrin and alpha2-antiplasmin dependent.
Nielsen VG
Blood Coagul Fibrinolysis; 2010 Sep; 21(6):584-7. PubMed ID: 20683324
[TBL] [Abstract][Full Text] [Related]
13. In vitro clot lysis as a potential indicator of thrombus resistance to fibrinolysis--study in healthy subjects and correlation with blood fibrinolytic parameters.
Colucci M; Scopece S; Gelato AV; Dimonte D; Semeraro N
Thromb Haemost; 1997 Apr; 77(4):725-9. PubMed ID: 9134650
[TBL] [Abstract][Full Text] [Related]
14. Thrombin activatable fibrinolysis inhibitor (TAFI) does not inhibit in vitro thrombolysis by pharmacological concentrations of t-PA.
Colucci M; D'Aprile AM; Italia A; Gresele P; Morser J; Semeraro N
Thromb Haemost; 2001 Apr; 85(4):661-6. PubMed ID: 11341502
[TBL] [Abstract][Full Text] [Related]
15. Acceleration of plasma clot lysis by an antibody to alpha 2-antiplasmin.
Reed GL; Matsueda GR; Haber E
Trans Assoc Am Physicians; 1988; 101():250-6. PubMed ID: 2480017
[No Abstract] [Full Text] [Related]
16. Fibrin clot lysis by tissue plasminogen activator (tPA) is impaired in plasma from pediatric patients undergoing orthotopic liver transplantation.
Leaker MT; Brooker LA; Mitchell LG; Weitz JI; Superina R; Andrew ME
Transplantation; 1995 Jul; 60(2):144-7. PubMed ID: 7624956
[TBL] [Abstract][Full Text] [Related]
17. Highly stable plasminogen activator inhibitor type one (VLHL PAI-1) protects fibrin clots from tissue plasminogen activator-mediated fibrinolysis.
Jankun J; Aleem AM; Selman SH; Skrzypczak-Jankun E; Lysiak-Szydlowska W; Grafos N; Fryer HJ; Greenfield RS
Int J Mol Med; 2007 Nov; 20(5):683-7. PubMed ID: 17912461
[TBL] [Abstract][Full Text] [Related]
18. Turbulent axially directed flow of plasma containing rt-PA promotes thrombolysis of non-occlusive whole blood clots in vitro.
Tratar G; Blinc A; Strukelj M; Mikac U; Sersa I
Thromb Haemost; 2004 Mar; 91(3):487-96. PubMed ID: 14983224
[TBL] [Abstract][Full Text] [Related]
19. [Measurements of plasmin-alpha 2 plasmin inhibitor complex and FDP.D dimer levels in the fibrinolytic therapy of acute pulmonary thromboembolism].
Yamasawa F; Hasegawa N; Asano K; Sayama K; Fujita H; Urano T; Aoki T; Ishizaka A; Kanazawa M; Kawashiro T
Kokyu To Junkan; 1992 Jul; 40(7):685-90. PubMed ID: 1387724
[TBL] [Abstract][Full Text] [Related]
20. Fibrin-specificity of a plasminogen activator affects the efficiency of fibrinolysis and responsiveness to ultrasound: comparison of nine plasminogen activators in vitro.
Sakharov DV; Barrertt-Bergshoeff M; Hekkenberg RT; Rijken DC
Thromb Haemost; 1999 Apr; 81(4):605-12. PubMed ID: 10235448
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]